Τίτλος:
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated
locally advanced or metastatic urothelial carcinoma (mUC): Immune
biomarkers, tumor mutational burden (TMB), and clinical outcomes from
the phase III IMvigor211 study.
Συγγραφείς:
Powles, Thomas
Loriot, Yohann
Ravaud, Alain
Vogelzang,
Nicholas J.
Duran, Ignacio
Retz, Margitta
De Giorgi, Ugo and
Oudard, Stephane
Bamias, Aristotelis
Koeppen, Hartmut
Leng,
Ning
Kadel, Edward E.
Hegde, Priti S.
Cui, Na
Shen,
Xiaodong
Derleth, Christina Louise
Green, Marjorie C. and
Banchereau, Romain
Mariathasan, Sanjeev
Van Der Heijden, Michiel
Simon
